Therefore, understanding the crosstalk between these identified biomarkers and immune cells, specifically neutrophils and CD4+ T cells, provides insights into the underlying mechanisms of CAD progression in IBD patients. This evidence concerns the gene CD4 and inflammatory bowel disease.